Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ebiom.2021.103410 http://scihub22266oqcxt.onion/10.1016/j.ebiom.2021.103410 34098342!8176920!34098342     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       EBioMedicine 2021 ; 68 (ä): 103410 Nephropedia Template TP {{tp|p=34098342|t=2021. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity |pdf=|usr=}}{{34098342}} gab.com Text SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity JO: EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=34098342 #FOAvip BACKGROUND: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed. METHODS: We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3(rd) and July 9(th) 2020, at least 14 days after COVID-19 symptom recovery. The participants had experienced a range of disease severities from asymptomatic to severe. We collected plasma, serum and PBMC's for analysis of SARS-CoV-2 specific antibody response by Meso Scale analysis including other coronavirus strains, ACE2 competition, IgA ELISA, pseudovirus neutralization capacity, and dextramer flow cytometry analysis of CD8(+) T cells. The immunological outcomes were compared amongst severity groups within the cohort, and 10 pre-pandemic SARS-CoV-2 negative controls. FINDINGS: We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8(+) T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2(+) individuals. INTERPRETATION: The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8(+) T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity. FUNDING: This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B). Twit Text FOAVip SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity ????EBioMedicine http://www.kidney.de/pget.php?&tw=1&pmid=34098342 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34098342 #FOAvip English Wikipedia <ref>{{Cite pmid|34098342}}</ref> SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity #MMPMID34098342 Nielsen SS; Vibholm LK; Monrad I; Olesen R; Frattari GS; Pahus MH; Hojen JF; Gunst JD; Erikstrup C; Holleufer A; Hartmann R; Ostergaard L; Sogaard OS; Schleimann MH; Tolstrup M EBioMedicine 2021[Jun]; 68 (ä): 103410 PMID34098342show ga BACKGROUND: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed. METHODS: We included 203 recovered SARS-CoV-2 infected patients in Denmark between April 3(rd) and July 9(th) 2020, at least 14 days after COVID-19 symptom recovery. The participants had experienced a range of disease severities from asymptomatic to severe. We collected plasma, serum and PBMC's for analysis of SARS-CoV-2 specific antibody response by Meso Scale analysis including other coronavirus strains, ACE2 competition, IgA ELISA, pseudovirus neutralization capacity, and dextramer flow cytometry analysis of CD8(+) T cells. The immunological outcomes were compared amongst severity groups within the cohort, and 10 pre-pandemic SARS-CoV-2 negative controls. FINDINGS: We report broad serological profiles within the cohort, detecting antibody binding to other human coronaviruses. 202(>99%) participants had SARS-CoV-2 specific antibodies, with SARS-CoV-2 neutralization and spike-ACE2 receptor interaction blocking observed in 193(95%) individuals. A significant positive correlation (r=0.7804) between spike-ACE2 blocking antibody titers and neutralization potency was observed. Further, SARS-CoV-2 specific CD8(+) T-cell responses were clear and quantifiable in 95 of 106(90%) HLA-A2(+) individuals. INTERPRETATION: The viral surface spike protein was identified as the dominant target for both neutralizing antibodies and CD8(+) T-cell responses. Overall, the majority of patients had robust adaptive immune responses, regardless of their disease severity. FUNDING: This study was supported by the Danish Ministry for Research and Education (grant# 0238-00001B) and The Danish Innovation Fund (grant# 0208-00018B). |Adaptive Immunity[MESH] |Adult[MESH] |Aged[MESH] |Angiotensin-Converting Enzyme 2/*metabolism[MESH] |Animals[MESH] |Antibodies, Neutralizing/*blood[MESH] |Antibodies, Viral/blood[MESH] |CD8-Positive T-Lymphocytes/metabolism[MESH] |COVID-19/*immunology/virology[MESH] |Cell Line[MESH] |Denmark[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2/*immunology/pathogenicity[MESH] |Severity of Illness Index[MESH] |Spike Glycoprotein, Coronavirus/*immunology[MESH]SARS-CoV-2 elicits robust adaptive immune responses regardless of dise(epmc).pdf DeepDyve Pubget Overpricing